Alumis (ALMS) Net Cash Flow (2023 - 2025)
Alumis (ALMS) reported Net Cash Flow of $24.4 million for Q4 2025, up 155.75% year-over-year from $9.5 million in Q4 2024, and up 128.11% on a QoQ basis from -$86.9 million in Q3 2025.
Alumis (ALMS) has 3 years of Net Cash Flow data on file, last reported at $24.4 million in Q4 2025.
- Quarterly Net Cash Flow rose 155.75% year-over-year to $24.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$80.3 million (down 165.04% YoY) and the FY2025 annual result came in at -$79.6 million, down 164.44% from the prior year.
- Net Cash Flow improved to $24.4 million in Q4 2025 per ALMS's latest filing, from -$86.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $66.0 million in Q1 2024 and bottomed at -$86.9 million in Q3 2025.
- The 3-year median for Net Cash Flow is $7.4 million (2023), against an average of $939900.0.
- Peak annual rise in Net Cash Flow reached 327.34% in 2024, while the deepest fall reached 434.58% in 2024.
- Tracing ALMS's Net Cash Flow over 3 years: stood at -$8.2 million in 2023, then plunged by 434.58% to -$43.8 million in 2024, then jumped by 155.75% to $24.4 million in 2025.
- Per Business Quant, the three latest ALMS Net Cash Flow figures stand at $24.4 million (Q4 2025), -$86.9 million (Q3 2025), and $23.1 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 625.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 457.40 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -152.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 60.68 Mn |
| 10 | Alumis | 1.84 Bn | 1.75 Bn | - | 24.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 24.42 Mn |
| Dec 31, 2025 | 24.42 Mn |
| Sep 30, 2025 | -86.88 Mn |
| Sep 30, 2025 | -86.88 Mn |
| Jun 30, 2025 | 23.06 Mn |
| Jun 30, 2025 | 23.06 Mn |
| Mar 31, 2025 | -40.93 Mn |
| Mar 31, 2025 | -40.93 Mn |
| Dec 31, 2024 | -43.81 Mn |
| Dec 31, 2024 | -43.81 Mn |
| Sep 30, 2024 | 58.15 Mn |
| Sep 30, 2024 | 58.15 Mn |
| Jun 30, 2024 | 43.12 Mn |
| Jun 30, 2024 | 43.12 Mn |
| Mar 31, 2024 | 66.04 Mn |
| Mar 31, 2024 | 66.04 Mn |
| Dec 31, 2023 | -8.20 Mn |
| Dec 31, 2023 | -8.20 Mn |
| Sep 30, 2023 | -25.58 Mn |
| Sep 30, 2023 | -25.58 Mn |